PlayAGS, Inc. – Consensus Indicates Potential 89.5% Upside

DirectorsTalk Interviews

PlayAGS, Inc. with ticker code (AGS) now have 8 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 16 and 6 with the average target price sitting at 11.5. With the stocks previous close at 6.07 this indicates there is a potential upside of 89.5%. The 50 day moving average now sits at 6.01 and the 200 day moving average is 6.52. The market capitalisation for the company is $250m. Company Website: https://www.playags.com

The potential market cap would be $474m based on the market concensus.

PlayAGS, Inc. designs and supplies gaming products and services for the gaming industry in the United States and internationally. It operates through three segments: Electronic Gaming Machines (EGM), Table Products, and Interactive Games (Interactive). The EGM segment offers various video slot titles for the marketplace; and EGM cabinets, including the Orion Starwall, Orion Curve Premium, Big Red, Orion Portrait, Orion Slant, Orion Curve, Orion Upright, and ICON. This segment also provides conversion kits that allow existing game titles to be converted to other game titles offered within that operating platform. It serves Class II Native American and Mexico, as well as Class III Native American, commercial, and charitable jurisdictions. The Table Products segment offers table products, including live felt table games, side bet offerings, progressives, card shufflers, signage, and other ancillary table game equipment, as well as table technology related to blackjack, poker, baccarat, craps, and roulette. This segment also provides Dex S, a single deck card shuffler for poker tables. Its brands include In Bet, Buster Blackjack, Double Draw Poker, and Criss Cross Poker. The Interactive segment offers a platform for business-to-business content aggregation used by real-money gaming and sports-betting partners; and business-to-consumer social casino games through its mobile app, Lucky Play Casino. The company was formerly known as AP Gaming Holdco, Inc. and changed its name to PlayAGS, Inc. in December 2017. PlayAGS, Inc. was incorporated in 2005 and is headquartered in Las Vegas, Nevada.

Share on:
Find more news, interviews, share price & company profile here for:

    Likewise granted approval for 20,000 sq ft expansion of Newport facility

    Likewise Group has received planning permission to extend its Newport warehouse by 20,000 sq ft, creating a 55,000 sq ft distribution hub. The development will be funded through internal cash flow.

    Cerillion secures £17.3m follow-on contracts with major European customer

    Cerillion has signed two agreements worth a combined £17.3 million with an existing European customer, following an £8 million services contract announced in May 2025.

    Avation reports US$110m revenue and strengthened balance sheet for FY25

    Avation expects revenue of around US$110 million for the year to 30 June 2025. The company has reduced outstanding bond debt to US$298 million through repurchases and improved its credit ratings with Moody’s and Fitch.

    JPMorgan European Discovery Trust reports strong performance uplift in latest factsheet

    JPMorgan European Discovery Trust reported a 5.37% share price rise in July 2025, outpacing NAV and its benchmark. Year-to-date, the share price is up 34.17%, supported by strong small-cap performance and effective stock selection.

    Golden Matrix reports record August revenue of $17.8m, up 18% year-on-year

    Golden Matrix posted record August revenues of $17.8m, up 18% from last year, with July revenues also rising 24% to $15.7m. Strong performance came from Meridianbet’s sports betting and RKings’ tournaments, positioning the group for record Q3 results.

    HUTCHMED to present new lung cancer and oncology data at WCLC and CSCO 2025

    HUTCHMED announced that updated data on savolitinib in NSCLC and other pipeline compounds will be presented at the World Conference on Lung Cancer in Barcelona and the CSCO Annual Meeting in China this September. Presentations include studies on savolitinib, surufatinib, fruquintinib and first-in-human results for HMPL-653.

      Search

      Search